BioVersys Advances Tuberculosis Treatment with AlpE

BioVersys AG, based in Basel, Switzerland, has published pre-clinical data in Nature Communications, highlighting the innovative mechanism of Alpibectir when combined with Ethionamide (referred to as AlpE). This combination targets Mycobacterium tuberculosis, the pathogen causing TB, particularly in drug-resistant strains.

Alpibectir works by enhancing the bioactivation of ethionamide, proving effective in both in vitro and in vivo studies against resistant TB strains. Ongoing clinical trials include a Phase 2b for pulmonary TB by GlaxoSmithKline (GSK) and BioVersys' study on meningeal TB.

The publication emphasizes AlpE's potential as a novel treatment option. With funding from the EU's Innovative Medicines Initiative, Alpibectir is positioned to significantly impact TB treatment strategies, offering new hope for enhancing current anti-TB regimens.